IMM01-STEM

Phase 2Biologic

IImmunis, Inc.

IMM01-STEM is one of 66 biologic programs targeting Obesity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityActive, not recruiting

OsteoarthritisActive, not recruiting

Muscle WeaknessActive, not recruiting

ObesityPreclinical

Active, not recruiting

OsteoarthritisPhase 1/Phase 2

Active, not recruiting

Muscle WeaknessPhase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 2

Ilaris

Novartis

Preclinical

2 3

Toradol

Roche

Preclinical

1 4

IMM01-STEM

IImmunis, Inc.

Phase 2

1 5

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 6

Cataflam

Glucophage

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 10

Catapres

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Muscle Weakness

NCT06600581

Clinical

Trials by Indication[1]

Obesity1 trial

INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITY

Temporarily not available·IImmunis, Inc.··NCT06784297

Osteoarthritis1 trial

Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

Recruiting·IImmunis, Inc.·Phase 1/2·NCT05211986·28 enrolled

Muscle weakness1 trial

Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness

Active, not recruiting·IImmunis, Inc.·Phase 2·NCT06600581·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for IMM01-STEM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMM01-STEM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMM01-STEM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immunis, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IImmunis, Inc.

IMM01-STEM

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Obesity1 trial

Osteoarthritis1 trial

Muscle weakness1 trial

References

Drug Info

Quick Facts

Related News